Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

The secondary objective of this study is to describe safety, persistency, and tolerability
of SOF/LED in patients with HCV-6.

Inclusion Criteria:

1. Male or female, age ≥18 years

2. HCV genotype 6 or indeterminate and later assessed at Screening and confirmed as
genotype 6

3. Selected to start on treatment by their treating providers

4. Willing and able to provide informed consent

5. Able to comply with dosing instructions for study drug administration and able to
complete the study schedule of assessments

6. Females of childbearing potential must have a negative serum pregnancy test at
Screening and a negative pregnancy test on Baseline

7. Male subjects and female subjects of childbearing potential who engage in
heterosexual intercourse must agree to use protocol specified method(s) of
contraception

8. Lactating females must agree to discontinue nursing before the study drug is
administered

Exclusion Criteria:

1. Previous recipient of a liver transplant

2. Co-infection with human immunodeficiency virus (HIV) or hepatitis B (HBV)